DUBLIN--(BUSINESS WIRE)--Oct 21, 2019--

The "Keratoconus - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Keratoconus - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Keratoconus pipeline landscape is provided which includes the disease overview and Keratoconus treatment guidelines.

The assessment part of the report embraces in depth Keratoconus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keratoconus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Keratoconus Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Keratoconus targeted therapeutics development with respective active and dormant or discontinued projects. Keratoconus pipeline report covers 3 + companies. Some of the key players include iVeena Delivery Systems (IVMED-80), etc.

Scope of the report

  • The Keratoconus report provides an overview of therapeutic pipeline activity for Keratoconus across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Keratoconus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Keratoconus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Keratoconus

Key Topics Covered:

1. Report Introduction

2. Keratoconus (Conical cornea)

2.1. Keratoconus Disease Overview

2.2. Keratoconus History

2.3. Keratoconus Symptoms

2.4. Keratoconus Causes

2.5. Keratoconus Pathophysiology

2.6. Keratoconus Diagnosis

2.6.1. Diagnostic Guidelines

3. Keratoconus Current Treatment Patterns

3.1. Treatment Guidelines

4. Keratoconus - An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Keratoconus companies collaborations, Licensing, Acquisition - Deal Value Trends Assessment Summary

4.1.2. Keratoconus Collaboration Deals Company-Company Collaborations (Licensing/Partnering) Analysis Keratoconus Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Keratoconus Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. Keratoconus-Products Analysis

6.1. Product Profiles

6.1.1. IVMED-80: iVeena Delivery Systems Product Description Product Overview Mechanism of Action Research and Development Clinical Studies Detailed Study Description Study Results Clinical Trials: Tabular View Product Development Activities Tabulated Product Summary General Description Table

7. Recent Technologies

8. Keratoconus Key Companies

8.1. ISTA Pharmaceuticals

8.2. iVeena Delivery Systems

8.3. Mimetogen Pharmaceuticals

9. Keratoconus Key Products

9.1. Hyaluronidase (Keraform)

9.2. IVMED 80

9.3. Research programme: eye disorder therapies

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Keratoconus - Unmet Needs

12. Keratoconus - Future Perspectives

13. Appendix

Companies Mentioned

  • ISTA Pharmaceuticals
  • iVeena Delivery Systems
  • Avedro
  • Pfizer
  • Allergan
  • Mimetogen Pharmaceuticals
  • Merck & Co
  • AxeroVision
  • Nevakar
  • AstraZeneca
  • Oyster Point Pharmaceuticals
  • Celgene Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tyuipx

View source version on businesswire.com:https://www.businesswire.com/news/home/20191021005453/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/21/2019 10:08 AM/DISC: 10/21/2019 10:08 AM


Copyright Business Wire 2019.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.